Cargando…
Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of trep...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641714/ https://www.ncbi.nlm.nih.gov/pubmed/23662183 http://dx.doi.org/10.4103/2045-8932.109926 |
_version_ | 1782268047869870080 |
---|---|
author | Raina, Amresh Coons, James C. Kanwar, Manreet Murali, Srinivas Sokos, George Benza, Raymond L. |
author_facet | Raina, Amresh Coons, James C. Kanwar, Manreet Murali, Srinivas Sokos, George Benza, Raymond L. |
author_sort | Raina, Amresh |
collection | PubMed |
description | Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of treprostinil has provided clinicians with an alternative to continuous SC or IV treprostinil in appropriate patients. Stable PAH patients whose quality of life has been dramatically impacted by side effects of parenteral therapy or those who have had recurrent, life-threatening bloodstream infections but are otherwise responding well to treatment may be the candidates for continuing prostacyclin therapy with inhaled treprostinil. However, there is little clinical experience with transitioning patients from parenteral to inhaled treprostinil. We present the results of two cases that highlight important considerations in transitioning patients from parenteral to inhaled therapy, including the pharmacologic and clinical equivalence of formulations, dose titration of formulations and suggested criteria for patient selection. |
format | Online Article Text |
id | pubmed-3641714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-36417142013-05-09 Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension Raina, Amresh Coons, James C. Kanwar, Manreet Murali, Srinivas Sokos, George Benza, Raymond L. Pulm Circ Case Report Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of treprostinil has provided clinicians with an alternative to continuous SC or IV treprostinil in appropriate patients. Stable PAH patients whose quality of life has been dramatically impacted by side effects of parenteral therapy or those who have had recurrent, life-threatening bloodstream infections but are otherwise responding well to treatment may be the candidates for continuing prostacyclin therapy with inhaled treprostinil. However, there is little clinical experience with transitioning patients from parenteral to inhaled treprostinil. We present the results of two cases that highlight important considerations in transitioning patients from parenteral to inhaled therapy, including the pharmacologic and clinical equivalence of formulations, dose titration of formulations and suggested criteria for patient selection. Medknow Publications 2013 /pmc/articles/PMC3641714/ /pubmed/23662183 http://dx.doi.org/10.4103/2045-8932.109926 Text en Copyright: © Pulmonary Circulation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Raina, Amresh Coons, James C. Kanwar, Manreet Murali, Srinivas Sokos, George Benza, Raymond L. Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
title | Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
title_full | Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
title_fullStr | Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
title_full_unstemmed | Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
title_short | Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
title_sort | transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641714/ https://www.ncbi.nlm.nih.gov/pubmed/23662183 http://dx.doi.org/10.4103/2045-8932.109926 |
work_keys_str_mv | AT rainaamresh transitioningfromparenteraltreprostiniltoinhaledtreprostinilinpatientswithpulmonaryarterialhypertension AT coonsjamesc transitioningfromparenteraltreprostiniltoinhaledtreprostinilinpatientswithpulmonaryarterialhypertension AT kanwarmanreet transitioningfromparenteraltreprostiniltoinhaledtreprostinilinpatientswithpulmonaryarterialhypertension AT muralisrinivas transitioningfromparenteraltreprostiniltoinhaledtreprostinilinpatientswithpulmonaryarterialhypertension AT sokosgeorge transitioningfromparenteraltreprostiniltoinhaledtreprostinilinpatientswithpulmonaryarterialhypertension AT benzaraymondl transitioningfromparenteraltreprostiniltoinhaledtreprostinilinpatientswithpulmonaryarterialhypertension |